Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19
- Conditions
- SARS-CoV2COVID
- Registration Number
- NCT04456075
- Lead Sponsor
- Heidelberg University
- Brief Summary
Approximately 15% of patients with SARS-CoV-2 infection / COVID-19 develop a severe clinical course. This leads to hospitalization and potentially life threatening complications such as pneumonia and respiratory failure. Predictors for early detection and risk stratification are urgently needed. Moreover, only scarce information is available for long-term follow-up and late complications associated with infection. We therefore aimed to find predictors for severe courses of the novel disease as well as to establish strategies for therapeutic monitoring and follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- SARS-CoV-2 infection / COVID 19
- invasive ventilation
- respiratory failure at admission
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method D5-20 1-6 months (outpatients, follow up) frequency dependence of resistance as measured by oscillometry
FEV1/FVC 1-6 months (outpatients, follow up) forced expiratory volume in 1 s / forced vital capacity (as measured by spirometry)
TLCO 1-6 months (outpatients, follow up) Transfer factor for carbon monoxide
- Secondary Outcome Measures
Name Time Method comorbidities at hospital admission and each follow (every 1-6 months) structured questionnaire
clinical symptoms 3-5 days intervals (inpatients), 1-6 months (outpatients, follow up) structured qualitative questionnaire
St. George's Respiratory Questionnaire total score 3-5 days intervals (inpatients), 1-6 months (outpatients, follow up) validated questionnaire (scores range from 0 to 100, with higher scores indicating more limitations)
Trial Locations
- Locations (1)
Thoraxklinik at Heidelberg University
🇩🇪Heidelberg, Germany